**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 54717

**Manuscript type:** REVIEW

**Non-invasive tests for the prediction of primary hepatocellular carcinoma**

Marasco G*et al*. Non-invasive prediction of HCC

Giovanni Marasco, Antonio Colecchia, Giovanni Silva, Benedetta Rossini,Leonardo Henry Eusebi, Federico Ravaioli, Elton Dajti, Luigina Vanessa Alemanni, Luigi Colecchia, Matteo Renzulli, Rita Golfieri, Davide Festi

**Giovanni Marasco, Giovanni Silva, Benedetta Rossini, Leonardo Henry Eusebi, Federico Ravaioli, Elton Dajti, Luigina Vanessa Alemanni, Luigi Colecchia, Davide Festi**, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna 40138, Italy

**Antonio Colecchia**, Unit of Gastroenterology, Borgo Trento University Hospital of Verona, Verona 37126, Italy

**Matteo Renzulli, Rita Golfieri**, Radiology Unit, Sant’Orsola Malpighi Hospital, University of Bologna, Bologna 40138, Italy

**Author contributions:** Marasco G, Colecchia C and Festi D designed research; Silva G, Rossini B, Ravaioli F, Dajiti E, Alemanni LV, Colecchia G, Renzulli M and Golfieri R performed research; Marasco G, Colecchia C, Silva G and Festi D drafted the manuscript; Rossini B, Alemanni LV drafted the tables; Eusebi LH revised the English language; all authors revised and approved the final version of the manuscript.

**Corresponding author: Giovanni Marasco, MD, PhD, Academic Fellow, Academic Research, Research Fellow,** Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Via Massarenti 9, Bologna 40138, Italy. giovannimarasco89@gmail.com

**Received:** February 14, 2020

**Revised:** April 8, 2020

**Accepted:** June 12, 2020

**Published online:**

**Abstract**

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world and it is one of the main complications of cirrhosis and portal hypertension. Even in the presence of a well-established follow-up protocol for cirrhotic patients, to date poor data are available on predictive markers for primary HCC occurrence in the setting of compensated advanced chronic liver disease patients (cACLD). The gold standard method to evaluate the prognosis of patients with cACLD, beyond liver fibrosis assessed with histology, is the measurement of the hepatic venous pressure gradient (HVPG). An HVPG ≥10 mmHg has been related to an increased risk of HCC in cACLD patients. However, these methods are burdened by additional costs and risks for patients and are mostly available only in referral centers. In the last decade increasing research has focused on the evaluation of several, simple, non-invasive tests (NITs) as predictors of HCC development. We reviewed the currently available literature on biochemical and ultrasound-based scores developed for the non-invasive evaluation of liver fibrosis and portal hypertension in predicting primary HCC. We found that the most reliable methods to assess HCC risk were the liver stiffness measurement, the aspartate aminotransferase to platelet ratio index score and the fibrosis-4 index. Other promising NITs need further investigations and validation for different liver disease aetiologies.

**Key word:** Non-invasive test; Fibrosis-4 index; Hepatocellular carcinoma; Liver stiffness measurement; Spleen stiffness measurement; Albi

Marasco G, Colecchia A, Silva G, Rossini B,Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. *World J Gastroenterol* 2020; In press

**Core tip:** Poor data are available for the prediction of hepatocellular carcinoma in patients with compensated advanced chronic liver disease. Nowadays there is an increasing need for non-invasive tests for stratifying the risk of hepatocellular carcinoma. The most reliable tests for this purpose are the liver stiffness measurement, the aspartate aminotransferase to platelet ratio index score and the fibrosis-4 index, which more accurately assess liver fibrosis. Further research is needed to validate these encouraging results and to address the role of additional non-invasive tests to better evaluate portal hypertension degree in different liver disease aetiologies.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing about 90% of the cases[1]. It is the fifth most common malignant tumor in the world and the third most frequent cause of cancer-related death globally, with more than 600000 deaths per year[2–5]. Liver cirrhosis represents a major risk factor for HCC; indeed, 90% of hepatocellular carcinomas are related to cirrhosis and one-third of cirrhotic patients develop HCC during their lifetime[2,5].

The major driver of the HCC development is the degree of liver fibrosis, historically assessed with a semi-quantitative histologic evaluation[6,7], even though sampling variability and underrepresentation of liver biopsy[8] hampers its robust determination[9]. Exceptions to this postulate are mainly represented by HCC arisen in hepatitis B[10] and non-alcoholic fatty liver disease[11], since their carcinogenetic mechanisms are less dependent on liver fibrosis. Nowadays liver biopsy, previously considered the diagnostic method of choice for evaluating liver fibrosis, is a procedure confined only to specific and limited diagnostic questions in complex liver diseases[12]. Indeed, several limitations for its extensive use have been reported: besides the need for physician and pathologists with high expertise, it is a costly and invasive procedure[12].

Moreover, HCC develops more frequently in patients with cirrhosis complicated by portal hypertension (PH), since PH plays an important role in liver carcinogenesis. Currently, the measurement of the hepatic venous pressure gradient (HVPG) represents the gold standard method for predicting the progression of cirrhosis and the occurrence of its complications, including HCC[13,14]. Only two studies explored the predictive role of HVPG for primary HCC development; in the first by Ripoll *et al*[14] the authors concluded that an HVPG ≥ 10 mmHg was able to predict primary HCC development; in parallel, Kim *et al*[15] in a cohort of alcoholic liver disease patients also concluded that HVPG can be used to predict the development of HCC. However, HVPG is an invasive and risky method and it is not available in all liver units. For these reasons, several research groups have proposed to use non-invasive tools (NITs) as an alternative to liver biopsy and HVPG for predicting the development of primary HCC. The increasing need for NITs in several scenarios of patients with liver cirrhosis has also been recently addressed by the guidelines of the European Society for the Study of the Liver[12]. The aim of this review is to summarize the available literature on the recent advances in the evaluation of the different non-invasive tests for predicting primary HCC occurrence.

**BIOCHEMICAL-BASED NITs**

***Aspartate aminotransferase to platelet ratio index***

The aspartate aminotransferase (AST) to platelet ratio index (APRI) is a biochemical score which has a potential utility in predicting the risk of primary HCC[16]. The APRI was introduced by a study by Wai *et al*[17] and can be calculated using the following formula: AST (UI/L) × [100/platelet count (103/mm3)]. In a metanalysis on hepatitis C virus (HCV)-patients pooling data on APRI, an APRI value > 1.5 had the greater predictive value for diagnosing cirrhosis, whereas a value < 0.5 for ruling-out the presence of cirrhosis[18]. Thus, this score was developed as a non-invasive predictor of the progression to fibrosis in patients with chronic viral hepatitis. Over the years, several studies validated its role as markers of hepatic fibrosis[19,20] and subsequently tested its ability in predicting HCC (Table 1)[16,20–39].

One of the first correlation between APRI and HCC development was assessed by Hann *et al*[34] among hepatitis B virus (HBV) patients; APRI was shown to be a good prospective predictor of HCC, especially in the multivariate analysis (*P* trend = 0.008 in quartile analysis). In a later study by Kim *et al*[36] including 542 HBV patients, the authors reported an area under the receiver operative characteristic (AUROC) of 0.731 for APRI in predicting HCC, using a cut-off of 0.766.

In a study by Chen *et al*[35] the authors reported at multivariate analysis a prognostic role for APRI in both patients achieving or not sustained virologic response (SVR) in patients treated with peginterferon/ribavirin: in particular a post-treatment APRI ≥ 0.5 was associated with a hazard ratio (HR) of HCC development of 4.401 in SVR patients, whereas an APRI ≥ 1.5 with an HR of 10.905 in not SVR patients. Similarly, Ji *et al*[24] analyzed HCV patients who had achieved SVR after interferon-based antiviral treatment, showing that a post-treatment APRI ≥ 1.5 was associated with a higher incidence of HCC (*P* < 0.01). On the other hand, as new direct antiviral agents (DAA) are available, APRI index is lowered after the achievement of SVR[40], but still holds its predictive value in for HCC occurrence, even after SVR[29].

The prognostic value of APRI has been reported also in other settings beyond viral hepatitis. Kim *et al*[26] reported in a cohort of patients with alcoholic liver cirrhosis an AUROC of 0.61 for predicting HCC occurrence at 3 years. Cheung *et al*[22] also investigated the link between APRI and HCC development in patients with primary biliary cholangitis treated with ursodeoxycholic acid: an APRI at 1 year after treatment (APRI-r1) > 0.54 resulted as an independent risk factor for HCC (HR = 3.94, *P* = 0.043) with an AUROC of 0.77. In conclusion, since APRI cut-offs for cirrhosis and suffers of poor sensitivity it is very likely that also the predictive role for HCC development could be underestimated[41]. Several authors recommended APRI should be considered when liver stiffness measurement (LSM) is unavailable. On the other hand, in such conditions when a transaminase flare could be expected, the use of APRI is rather recommended[42]. However, we advise the use of this simple transaminase-based NIT which allows us to detect significant fibrosis and to stratify the risk of HCC only in resource-limited settings.

***Fibrosis-4 index***

The fibrosis-4 index (Fib-4) index was firstly proposed by Sterling *et al*[43] in an human immunodeficiency virus (HIV)/HCV cohort to assess the degree of hepatic fibrosis and it is based on four factors, included in the following equation: [age (years) × AST (UI/L)]/[platelet count × ALT (UI/L)]. A Fib-4 > 3.25 had a high specificity for ruling-in cirrhosis, while a value < 1.45 was the cut-off to rule-out cirrhosis.

As far as Fib-4 is concerned, various authors[44–48] have assessed its predictive value for primary HCC development (Table 2)[16,20,23,25–27,32,36,44–60].

Tseng *et al*[48] evaluated if Fib-4 was able to rule out HBV patients at lower risk of HCC development; considering treatment-naïve patients, those with a baseline Fib-4 < 1.29 had a significantly lower HCC risk, compared to those with baseline Fib-4 values ≥ 1.29 (HR 5.56, 95%CI: 3.93-7.86). Among patients who received nucleoside analogues (NUC) treatments, none of 326 subjects with baseline Fib-4 < 1.29, ALT < 40 U/L, and HBsAg < 1000 IU/mL developed hepatocellular carcinoma. Therefore, a cut-off value of Fib-4 < 1.29 showed a good prognostic performance.

Interesting results were also reported in two different studies by Suh *et al*[46,47]. The first one was conducted on chronic hepatitis B carriers[46]: it was observed that, compared to subjects with Fib-4 < 1.25, subjects with Fib-4 between 1.7 and 2.4 had an adjusted HR of 4.57 (95%CI: 1.50-13.92), and subjects with Fib-4 ≥ 2.4 had an aHR of 21.34 (95%CI: 7.73-58.92) for HCC occurrence. In addition, Fib-4 was shown to have incremental predictive value to US-liver cirrhosis for HCC development (C-index: 0.701 *vs* 0.831, *P* = 0.001). Fib-4 resulted also a better predictor of HCC incidence, compared to US-liver cirrhosis (C-index: 0.775 *vs* 0.701, *P* = 0.040).

Kanwal *et al*[45] evaluated a cohort of subjects with HCV-related disease, previously treated with DAAs reaching SVR; the group with Fib-4 > 3.25 showed an annual HCC incidence of 2.16%, against 0.45% among those with Fib-4 ranging from 1.45 to 3.25, and 0.3% of those with Fib-4 ≤ 1.45. Similar results came from a very large study from North America[56] exploring Fib-4 variations after SVR: a decrease in Fib-4 scores from ≥ 3.25 pre-SVR to < 3.25 post-SVR halved the risk of HCC. Interestingly, in this study[56] even in patients without cirrhosis and with a low risk of HCC, a pre-SVR Fib-4 score ≥ 3.25 (HCC risk 1.22%/year) and post-SVR Fib-4 scores ≥ 3.25 (HCC risk 2.39%/year) were associated with a high risk of HCC up to 10 years after SVR.

The same cut-off values used by Kanwal *et al*[45] were applied in a study by Park *et al*[44] which studied patients with HIV infection, most of whom had also HBV/HCV infection or history of alcohol abuse; in this cohort, the elevation of Fib-4 proved to be a strong predictive factor for HCC development (HR 3.6 for Fib-4 1.45- 3.25; HR 9.6 for Fib-4 > 3.25; *P* < 0.0001).

The second study of the aforementioned by Suh *et al*[47] was conducted on alcohol drinkers: compared to patients with Fib-4 values < 1.00, patients with Fib-4 values ≥ 1.75 and < 2.10 and patients with Fib-4 values ≥ 2.10 showed an aHRs of 5.18 (95%CI: 1.12-24) and 13.63 (95%CI: 3.77-49.33), respectively, for HCC development. Similarly, Fib-4 was a better predictive tool for HCC development if compared to US-assessed liver cirrhosis (C-index, 0.665 *vs* 0.527, *P* = 0.044).

As non-alcoholic fatty liver disease (NAFLD) is concerned, a study[57] from four European primary care databases representing the UK, the Netherlands, Italy and Spain, including 18 million adults, found that patients with NAFLD and non-alcoholic steatohepatitis (NASH) with high Fib-4 (> 2.67) score had an increased risk for HCC development compared to those with low Fib-4 (HR 25.2).

From a critical point of view, similarly to other serologic markers used in the evaluation of liver fibrosis, Fib-4 has some limitations, mainly because the index is influenced by age, race and could underestimate the presence of fibrosis in NAFLD[61,62]. Nevertheless, since it seems to be the most widely validated score for predicting cirrhosis and HCC, we still support its use as general and simple screening for the risk of HCC during the everyday clinical practice in the main settings of the liver cirrhosis as HBV, HCV and NAFLD/NASH patients.

***APRI and Fib-4 comparative studies***

Several research groups performed comparative studies on the ability of APRI and Fib-4 in predicting HCC; most of them have reported that both Fib-4 and APRI may be used together as predictors of HCC development to improve their predictive accuracy and to overcome the abovementioned limitations of each score. For example, Paik *et al*[16] stratified more than 1000 HBV patients into three groups: those with both APRI and Fib-4 above the proposed cut-off values, 0.5 and 1.45 respectively (Group 1), those with only one index above cut-offs (Group 2), and those with both indexes below (Group 3): they showed that hepatocellular carcinoma had highly different incidence rates in the 3 groups (13.9% in Group 1, 1.4% in Group 2, 1.2% in Group 3, *P* < 0.001); similarly, in the non-cirrhotic population the rates were 11.4% for Group 1, 1.5% for Group 2 and 0.4% for Group 3 (*P* < 0.001). This research suggested that the combined use of APRI and Fib-4 can be effective in stratifying the HCC risk and it may be preferred to the use of a single test[16]. Besides, Na *et al*[20] identified both APRI and Fib-4 as independent predictive tools for HCC in patients with chronic hepatitis C responsive to Interferon therapy. Indeed, the annual incidence of carcinoma was significantly higher in those patients with a post-treatment APRI $\geq $ 0.5 (1.67% *vs* 0.07%, *P* < 0.0001), as well as in those with a post-treatment Fib-4 ≥ 2.5 (1.49 *vs* 0.01, *P* = 0.0003). As regards to the HCV and the DAA setting, although a previous study[29] on a small cohort of patients did not find at multivariate analysis a predictive role for Fib-4 and APRI, a recent larger evaluation in the above-mentioned study by Kanwal *et al*[45] found that persistently high Fib-4 and APRI after HCV-eradication in both patients with and without cirrhosis was associated with an increased risk of HCC development.

Finally, a study by Peleg *et al*[55] in NAFLD patients explored the accuracy of APRI and Fib-4 in predicting the development of various malignancies (including HCC): the results showed that, with adjustments for gender, age, hypertension and type 2 diabetes, an APRI score > 1.5 (HR 4.94, 95%CI: 1.92–12.82, *P* = 0.0009) and a Fib-4 score > 2.67 (HR 6.12, 95%CI: 2.31–16.17, *P* = 0.0003) were associated with the occurrence of malignancies. Thus, according to recent publications, both APRI and Fib-4 can have a potential utility in predicting primary HCC development, with increased accuracy when combined. However, further research should be carried out to confirm these data in all the different liver disease aetiologies and to better explore the role of APRI and to define its best cut-off values, even though in most of the above-mentioned studies the predictive accuracy remained rather low. On the other hand, stronger data are available for the use of Fib-4 in the setting of HBV also during NUC therapy, in NAFLD as general screening of HCC risk and in HCV before and after eradication for a predictor of the risk to select patients that require long term surveillance.

***Forns index***

The index developed by Forns *et al*[63] in 2002, before the introduction of transient elastography techniques was first proposed as a non-invasive tool for the detection of patients with non-significant liver fibrosis. It is calculated using four variables (age, gamma glutamyl transferase levels, total cholesterol levels and platelet count), with the following formula: 7.811 - 3.131 × ln [platelet count (109/L)] + 0.781 × ln [gamma glutamyl transferase (IU/L)] + 3.467 × ln [age (years)] – 0.014 × [cholesterol (mg/dL)]. The first studies on Forns index (FI) highlighted its accuracy in identifying patients with different stages of fibrosis and cirrhosis[63,64]. In recent years, some authors have also tried to evaluate the usefulness of this score for HCC prediction. A study by Toyoda *et al*[21], conducted on HCV patients responsive to antiviral therapy, evaluated the efficacy of various fibrosis markers (FI, APRI and Fib-4) to detect patients with low risk of developing HCC after SVR. All three scores performed well, but pre-treatment FI seemed to be the most accurate one; patients with a FI < 5.34 had a significantly lower HCC incidence compared to those with values above 5.34 (*P* = 0.0012). Besides, no subjects with low FI developed HCC after SVR, whereas HCC occurred both in patients with low APRI (9 cases) and patients with low Fib-4 (5 cases). These results showed that baseline FI (calculated before antiviral therapy) may be used to detect patients who can end the HCC surveillance program after the eradication of HCV.

Other significant findings were reported by D’Ambrosio *et al*[65], who carried out a prospective study on patients who achieved SVR after interferon therapy (*n* = 38); the univariate analysis showed that FI > 6.9 resulted as a risk factor for HCC development (HR 12.8, 95%CI:1.14-143.9; *P* = 0.039).

FI has shown promising results, but its value needs to be confirmed by further studies, with a higher number of HCC cases and in other aetiologies than HCV. However, the overall feeling is that FI is still mainly used for fibrosis assessment and has not easily entered clinical practice perhaps because of its complexity since it includes the evaluation of serum cholesterol which is not routinely performed in all centers.

***Lok index***

The Lok index is a non-invasive tool introduced by an American research group[66] as a predictor of cirrhosis development in patients with chronic hepatitis C. This index is based on simple laboratory parameters and it is calculated with the following formula: log odds (predicting cirrhosis) 5.56 − 0.0089 × platelet count (10 3/mm 3) + 1.26 × AST/ALT ratio + 5.27 × INR. Recently, a potential role of Lok Index in predicting HCC development has been explored. A retrospective study by an Egyptian group[67] analyzed the performances of eight different biochemical scores (King score, Fibro Q, AST-ALT ratio, APRI, Lok index, Goteborg University Cirrhosis Index, Fibro Alpha, and Biotechnology Research Center). The results showed a quite significant correlation between an increased Lok index (≥ 2.4) and HCC development (sensibility = 57.1%, specificity = 65.7%, with an AUROC = 0.66); however, the prognostic accuracy of this score proved to be worse than other indexes, especially the Fibro Alpha and the Biotechnology Research Center (AUROC 0.91 and 0.93 respectively), and not sufficient to propose it as a valid predictive tool. Interesting results were also reported in the previously mentioned study by D’Ambrosio *et al*[65], conducted on subjects who achieved SVR for HCV; the analysis showed that a post-SVR Lok index > 0.5 was correlated with an increased risk of developing HCC (HR = 6.24, 95%CI: 1.03-37.6; *P* = 0.046); in the HCC population, 3 out of 5 patients had Lok index > 0.5, whereas in the not-HCC cohort, only 5 out of 33 patients had Lok scores > 0.5 (*P* = 0.05). This study demonstrated that, in a subset of cirrhotic patients, the HCC risk remains high even after SVR, and this aspect may be detected using the Lok index, as well as the FI. Despite some promising results, at present the Lok score is predominantly used for the prediction of cirrhosis; further trials with larger cohorts are needed to deeper explore its role as an HCC predictor in the different liver disease cohorts beyond HCV.

***Albumin-bilirubin and platelet count-albumin-bilirubin scores***

Another biochemical index used in clinical practice is the albumin-bilirubin (ALBI) score, introduced by Johnson *et al*[68] to evaluate liver function in patients with hepatocellular carcinoma. It was initially proposed as an alternative to the Child-Pugh score to overcome some of the known limitations, such as the inclusion of non-objective parameters (ascites, encephalopathy). The ALBI score is based on serum levels of albumin and total bilirubin and can be calculated with the following formula: (log10 bilirubin [µmol/L] × 0.66) + (albumin [g/L] × -0.0852). Johnson and colleaguesalso proposed to stratify ALBI values into three grades (ALBI ≤ −2.60: grade 1; ALBI > −2.60 and ≤ −1.39: grade 2, ALBI > −1.39 : grade 3), that were associated to different outcomes[68]. Subsequently, other studies highlighted the accuracy of the ALBI score in assessing the liver function in subjects with HCC undergoing resection or other treatments (transarterial chemoembolization, transarterial radioembolization, thermic ablation)[69–72]. This score proved to be effective in predicting the patient’s clinical outcome, especially in terms of hepatic decompensation (HD) and post-treatment survival. More recently, an Italian research group[73] observed that, in a cohort of HCV patients treated with DAA therapy, an elevated ALBI score before DAA treatment was strongly correlated with the occurrence of HCC (HR: 2.35, 95%CI: 1.05-5.25, *P* = 0.038). According to Johnson’s cut-offs[68], subjects with ALBI grade 2 or 3 showed a significantly higher risk of developing HCC than those with ALBI grade 1 (HR: 2.71, 95%CI: 1.08–6.83, *P* = 0.01).

A more recent study by Fujita *et al*[74] evaluated the HCC-risk of 125 prospectively collected HCV patients, identifying 3 categories with different HCC-risk according to ALBI percentile distribution, which are from that at lower to higher risk: Q1 with ALBI score below -2.773, Q2 with ALBI score between -2.773 and -2.215 and Q3 with ALBI score above -2.215 at baseline (*P* < 0.05). More importantly, low ALBI scores at baseline inversely correlated with the HCC-free survival of the patient. Another model, the platelet count-albumin-bilirubin (PALBI) score, has been developed by integrating the platelet count, which acts as a surrogate for the degree of portal hypertension, into the ALBI score. This marker has proved to be a valid predictor of the overall survival among patients with HCC undergoing various treatments, such as resection, ablation or radiotherapy[75–77]. Other authors[78,79] have also reported that the PALBI score can be used to predict the outcome of both patients with decompensated cirrhosis and subjects with liver-related complications. However, at present, there is no available data about the application of the PALBI score in predicting the development of primary HCC. In conclusion, to date only a few studies evaluated the predictive role of ALBI score for HCC development and its use is limited as prognostic markers after HCC treatment; this could be due to the fact that this score provides an objective estimation of the hepatic reserve estimation not completely taking into account the carcinogenetic mechanisms related to advanced cirrhosis and portal hypertension. Moreover, ALBI scores variations are more likely in advanced stages of liver cirrhosis, when HCC is already expected.

***Indocyanine green retention test***

The indocyanine green retention test (ICG R15) is a widely-used method for the evaluation of hepatic function[80,81]. This test is based on the intravenous injection of a contrast agent, the ICG, which is eliminated by the bilious system. Fifteen minutes after the injection, the agent’s clearance is assessed: in subjects with preserved liver function, the retention rate of ICG is normally lower than 10%; a retention value above 10% indicates a reduced hepatic function. At present, this test plays a central role in the pre-operative assessment of HCC patients undergoing resection and helps surgeons plan the extent of hepatectomy.

Several studies[82,83] highlighted that ICG R15 could be used to detect, among patients with compensated cirrhosis, those at higher risk of developing portal hypertension and esophageal varices. Therefore, this test was proposed as a non-invasive tool to identify patients who need endoscopic surveillance. The study by Lisotti *et al*[84] underlined the correlation between high ICG R15 values and the occurrence of HD in subjects with cirrhosis and PH. It is worth mentioning that patients with an ICG R15 > 23% showed an HD incidence of 70% in the first 3 years after the evaluation; furthermore, 18 out of 134 patients developed an HCC during the follow-up period, while twelve of them had previously experienced at least one episode of HD.

Another study by Song *et al*[85] showed that ICG R15 > 10% is an independent risk factor for HCC recurrence in patients who underwent resection; in fact, subjects with ICG R15 > 10% had lower recurrence-free survival rates than the rest of the population. However, in literature there is no experimental data focused on the performance of ICG R15 in predicting primary HCC even if promising data have been highlighted in the setting of HCC recurrence. However, multiple confounding factors are involved in ICG flow and metabolism[86], and in addition, if compared to other available NITs it seems to be more inquiring, thus, we do not advise its routine use in HCC-risk assessment.

**ULTRASOUND BASED NITs**

***LSM***

In recent years, the measurement of liver stiffness using transient elastography (FibroScan®; Echosens, Paris, France) has been used to assess the degree of hepatic fibrosis and thus to evaluate the risk of related complications[87–89]. In the last decade, research was also focused on the correlation between LSM and HCC development. Studies reporting this correlation are reported in Table 3[49,60,89–120]. Several cross-sectional trials[89,110,117] demonstrated that the median values of liver stiffness in patients with HCC are significantly higher than in those without HCC.

One of these large prospective trial by Poynard *et al*[96] (*n* = 3927) on chronic hepatitis C patients found that LSM was predictive of severe liver-related complications (AUROC 0.77; *P* < 0.0001), including primary HCC (AUROC 0.86; *P* < 0.0001). Other authors tried to quantify with LSM the risk of developing primary HCC after DAAs therapy. Rinaldi *et al*[111] found that an LSM cut-off value of 27.8 kPa at baseline before treatment identified patients at high risk of HCC after DAA, whereas Corma-Gómez *et al*[121] found in an HIV/HCV cohort treated with DAA that also Fib-4 in addition to LSM was associated with HCC occurrence. Another recent study[60] carried out in patients undergoing DAA therapy found that baseline LSM > 30 kPa independently predicted de novo HCC, with a 3-year estimated incidence of 20% in these patients versus 5% in patients with LSM ≤ 30 kPa. In the same study, in a model without LSM but including LSM-spleen to platelet ratio score and Fib-4, the latter was found to be independently associated with de novo HCC occurrence.

Nevertheless, all these studies only highlighted this ‘static’ phenomenon, without analyzing the ‘dynamic’ correlation between the progression or regression of hepatic fibrosis and the risk of developing HCC. Because of this limitation, several longitudinal prospective studies have been recently conducted. The first one, published by a Japanese group on a large cohort of 866 subjects with chronic C hepatitis[115], proved that an LSM value > 10 kPa is an accurate predictor of increased HCC risk (LSM values 10.1-15 kPa, HR 16.7; LSM 15.1-20, HR 20.9; LSM 20.1- 25, HR 25.6; LSM > 25 kPa, HR 45.5; all with *P* < 0.001). In another prospective study carried out by Jung *et al*[90] on HBV patients it was noticed that subjects with LSM > 8 kPa had an increased HCC risk, and that the incidence of HCC was directly proportional to LSM values: for LSM 8.1-13 kPa, HR 3.07 (*P* = 0.047); for LSM 13.1-18 kPa, HR 4.68 (*P* = 0.012); for LSM 18.1-23 kPa, HR 5.55 (*P* = 0.009); for LSM > 23 kPa, HR 6.60 (*P* = 0.004). After a median follow-up of 18 mo, a second LSM was made to evaluate if changes over time were related to a variation in HCC risk: patients with baseline LSM ≤ 13 kPa and follow-up LSM > 13 kPa had a significantly higher incidence of HCC than those with both values ≤ 13 kPa (*P* < 0.001); on the contrary, subjects with baseline LSM > 13 kPa who experienced regression of LSM below 13 kPa during follow-up had a significantly lower incidence of HCC than those who maintained an LSM value > 13 kPa (*P* < 0.001). Therefore, this study demonstrated that LSM can be also used as a ‘dynamic’ predictor of HCC risk, since its changes over time cause variations in the probability of developing HCC. This dynamic aspect has also been studied by our research group, which evaluated liver stiffness in HCV patients before and after DAAs therapy[122]. The results of our study showed that subjects who developed HCC had a lower reduction of LSM (∆LS) than the rest of the cohort (-18.0% *vs* -28.9%, *P* = 0.005); a ∆LS < 30% resulted as an independent risk factor for HCC development at multivariate analysis. Another recent study on this topic, recently published by Pons *et al*[113], found that LSM < 10 kPa (HR 0.33; 95%CI: 0.11-0.96) and albumin levels (HR 0.08; 95%CI: 0.02-0.25), both evaluated during follow-up, were independently associated with the risk of HCC; moreover, the group with a combination of these two predictors led to an HCC incidence ratio ≥ 1.9/100 patient-years.

LSM has also been compared with other NITs. Chon *et al*[49] compared the performance of LSM in predicting HCC with other indexes, such as LSPS, APRI and Fib-4; among all, LSM proved to be the most accurate model (AUROC 0.789).

Since the epidemiology of the liver disease is rapidly changing in the last decade due to the outbreak of new antiviral therapies and changing in the general population lifestyle, increased attention has been addressed to the evaluation of the prognostic significance of NITs in non-alcoholic fatty liver disease/steatohepatitis. A Japanese study[112] including cACLD patients with different aetiologies found that in NAFLD patients the incidence of HCC development was significantly higher among those with LSM ≥ 5.4 kPa and CAP ≤ 265 dB/m than among others (HR 8.91, 95%CI: 1.47-67.97, *P* = 0.0192). A further study[123] on NAFLD patients was not able to find a cut-off value for HCC prediction, even though the authors reported an increased incidence of HCC with increasing LSM (< 12 kPa: 0.32%; 12-18 kPa: 0.58%; 18-38 kPa 9.26% and > 38 kPa: 13.3%).

In conclusion, LSM is a good prognostic test, better than other liver fibrosis NITs, for HCC development prediction in chronic liver disease due to different aetiologies. Notably, a repeated assessment over time of LSM in cirrhotic patients could be more accurate than a single evaluation in monitoring the risk of HCC, even after viral eradication.

***LSM-spleen to platelet ratio score***

The LSM-spleen to platelet ratio score (LSPS) is a biochemical index obtained using the following formula: LSM (kPa) × spleen diameter (mm)/platelet count. This score was firstly proposed as a predictive tool for high-risk oesophageal varices in patients with HBV-related cirrhosis[124], and thus also as a surrogate marker of portal hypertension. Subsequently, various authors[49,125,126] have highlighted the relationship between an elevated LSPS and an increased risk of developing primary HCC. In a study by Shin *et al*[125] on 227 subjects with chronic HBV infection, the 18 patients who developed HCC averagely had higher LSM values, a longer spleen diameter and a lower platelet count than the rest of the study population (all *P* < 0.05). In addition, a LSPS of 1.1-2.5 was associated with a HR of 2.0 (*P* = 0.032) for HCC and a LSPS > 2.5 implied an HR of 8.7 (*P* = 0.002)[125]. Other important results have been reported by Marzano *et al*[126], who enrolled HBV patients responsive to nucleot(s)ide analogues: subjects with a post-therapy LSPS < 0.62 showed a significantly lower incidence of HCC compared to those with values ≥ 0.62 (7% *vs* 36%, *P* = 0.001)[126]. Antiviral therapies generally lead to the regression of cirrhosis and to a lower incidence of complications in this kind of patients[127]. The study also showed that low LSPS values at the end of the therapy were related to a lower risk of HCC occurrence, as well as to more significant regression of portal hypertension. In the previously mentioned study by Chon *et al*[49], various scores were evaluated as HCC predictors in patients with chronic hepatitis B: LSM and LSPS (AUROC = 0.789 and 0.788, respectively) showed better predictive performances than aspartate aminotransferase-to-platelet ratio index, age-spleen-to-platelet ratio index, P2/MS, and Fib-4 (AUROC = 0.729, 0.756, 0.696, and 0.744, respectively). However, at multivariate analysis, LSM resulted as the only independent predictor of HCC (HR = 1.040, *P* = 0.006), whereas LSPS was not significant (HR 1.002, *P* < 0.05). Therefore, these good results on LSPS could be explained by the ability of both LSM and spleen to platelet score to evaluate either the degree liver fibrosis and the additional carcinogenetic mechanisms added by portal hypertension in advanced chronic liver disease. However, further validation studies of these scores are still needed.

***Spleen stiffness measurement***

During the last decade, the use of transient elastography has been extended to the measurement of spleen stiffness. This organ, differently from the liver, is involved in the hemodynamic modifications due to PH even at higher values of portal pressure. The level of spleen stiffness (SS) is, therefore strictly related to the degree of PH even for HVPG values above 10-12 mmHg[128,129]. Several studies highlighted an excellent correlation between SS measurement (SSM) and the degree of PH assessed by HVPG[130,131]. Several reasons could explain this phenomenon. Firstly, the position of the organ allows a downstream of the portal circle, the elevation of portal pressure causes a blood reflow through the splenic vein, which leads to spleen’s congestion; secondly, the abnormal portal pressure induces structural modifications of the spleen (such as hypertrophy of the red pulp) as well as the development of a hyperdynamic circulation, both factors that play a role in the increase of spleen stiffness[132–134]. Recent studies[135–137] have shown the excellent performance of SSM in predicting the presence of oesophageal varices[138–142] and the risk of cirrhosis-related complications. Colecchia *et al*[135] conducted a prospective study including patients with compensated cirrhosis finding that SSM > 54 kPa was able to predict the development of HD during follow-up, including ascites, variceal bleeding, encephalopathy and HCC. In the HCC setting, the same group[143] found that an SSM > 70 kPa was the only independent predictor of late HCC recurrence (more than 24 mo) after resection of primary HCC. The correlation between increased SSM and the development of HCC is probably based on the role of portal hypertension. Indeed, it has been demonstrated that PH causes alterations in the portal circle, such as intrahepatic shunts, veno-occlusive thrombotic lesions and sinusoidal capillarization, which lead to lower sinusoidal perfusion[144]. This local ischaemic condition may cause the production of HIF (hypoxia-induced factor) and other cytokines, which stimulate neo-angiogenesis and fibrogenesis in dysplastic nodules[145]; the proliferation of new blood vessels and the progression of fibrosis favour the carcinogenesis process. Thus, SSM can be considered a promising method, with better performances than LSM in assessing the PH degree. However, to date, no studies directly evaluated the role of SSM in predicting primary HCC.

**CONCLUSION**

Several prognostic models based on NITs have recently been proposed as HCC predictors in experimental trials. However, the evidence that non-invasive tests can easily and accurately predict the risk of developing hepatocellular carcinoma in clinical practice is still scarce.

The most reliable data is available on LSM which accurately reflects the severity of the liver disease. LSM is able to evaluate either liver fibrosis degree, inflammation and portal hypertension, which are the main pathogenetic players of HCC development and risk. Furthermore, LSM can be used dynamically for monitoring HCC risk over time in cirrhotic patients. However, more studies are needed to validate LSM results on different aetiologies, such as NAFLD, and to determine specific optimal cut-off, able to assess HCC risk for each etiology. Moreover, the predictive role of other NITs should be further investigated. Despite these limitations, NITs represent valid tools helping clinicians in their daily practice, and they soon may also play a role in implementing surveillance strategies for HCC.

**REFERENCES**

1 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

2 **Global Burden of Disease Liver Cancer Collaboration**, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, Fürst T, Hancock J, Hay SI, Hotez P, Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, Ogbo F, Patton G, Pereira DM, Pourmalek F, Qorbani M, Radfar A, Roshandel G, Salomon JA, Sanabria J, Sartorius B, Satpathy M, Sawhney M, Sepanlou S, Shackelford K, Shore H, Sun J, Mengistu DT, Topór-Mądry R, Tran B, Ukwaja KN, Vlassov V, Vollset SE, Vos T, Wakayo T, Weiderpass E, Werdecker A, Yonemoto N, Younis M, Yu C, Zaidi Z, Zhu L, Murray CJL, Naghavi M, Fitzmaurice C. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. *JAMA Oncol* 2017; **3**: 1683-1691 [PMID: 28983565 DOI: 10.1001/jamaoncol.2017.3055]

3 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]

4 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

5 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016; **66**: 7-30 [PMID: 26742998 DOI: 10.3322/caac.21332]

6 **Ioannou GN**, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2007; **5**: 938-945, 945.e1-945.e4 [PMID: 17509946 DOI: 10.1016/j.cgh.2007.02.039]

7 **Rodríguez-Díaz JL**, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Mendez-Reguera A, Martínez-Tlahuel JL, Gamboa-Domínguez A, Arrieta O. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. *Clin Oncol (R Coll Radiol)* 2007; **19**: 197-203 [PMID: 17359907 DOI: 10.1016/j.clon.2006.12.005]

8 **Regev A**, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 2002; **97**: 2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x]

9 **Germani G**, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Assessment of fibrosis and cirrhosis in liver biopsies: an update. *Semin Liver Dis* 2011; **31**: 82-90 [PMID: 21344353 DOI: 10.1055/s-0031-1272836]

10 **Levrero M**, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. *J Hepatol* 2016; **64**: S84-S101 [PMID: 27084040 DOI: 10.1016/j.jhep.2016.02.021]

11 **Mittal S**, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol* 2016; **14**: 124-31.e1 [PMID: 26196445 DOI: 10.1016/j.cgh.2015.07.019]

12 **European Association for Study of Liver**; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol* 2015; **63**: 237-264 [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006]

13 **Ripoll C**, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. *Gastroenterology* 2007; **133**: 481-488 [PMID: 17681169 DOI: 10.1053/j.gastro.2007.05.024]

14 **Ripoll C**, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. *J Hepatol* 2009; **50**: 923-928 [PMID: 19303163 DOI: 10.1016/j.jhep.2009.01.014]

15 **Kim MY**, Baik SK, Yea CJ, Lee IY, Kim HJ, Park KW, Kim HK, Suk KT, Kim JW, Kim HS, Kwon SO, Cha SH, Kim YJ, Koh SB, Chang SJ. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. *Eur J Gastroenterol Hepatol* 2009; **21**: 1241-1246 [PMID: 19455045 DOI: 10.1097/MEG.0b013e32832a21c1]

16 **Paik N**, Sinn DH, Lee JH, Oh IS, Kim JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. *Liver Int* 2018; **38**: 68-75 [PMID: 28581248 DOI: 10.1111/liv.13489]

17 **Wai CT**, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; **38**: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]

18 **Lin ZH**, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology* 2011; **53**: 726-736 [PMID: 21319189 DOI: 10.1002/hep.24105]

19 **Vallet-Pichard A**, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. *Hepatology* 2007; **46**: 32-36 [PMID: 17567829 DOI: 10.1002/hep.21669]

20 **Na SK**, Lee SJ, Cho YK, Kim YN, Choi EK, Song BC. Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy. *J Interferon Cytokine Res* 2019; **39**: 703-710 [PMID: 31216229 DOI: 10.1089/jir.2019.0049]

21 **Toyoda H**, Tada T, Tachi Y, Hirai T, Yasuda S, Honda T, Hayashi K, Ishigami M, Goto H, Kumada T. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV. *Antivir Ther* 2017; **22**: 185-193 [PMID: 27586087 DOI: 10.3851/IMP3081]

22 **Cheung KS**, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. *World J Gastroenterol* 2017; **23**: 7863-7874 [PMID: 29209127 DOI: 10.3748/wjg.v23.i44.7863]

23 **Nishikawa H**, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. *J Cancer* 2017; **8**: 152-161 [PMID: 28243319 DOI: 10.7150/jca.16523]

24 **Ji F**, Zhou R, Wang W, Bai D, He C, Cai Z, Shen Y, Wang S, Deng H, Li Z. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy. *J Interferon Cytokine Res* 2017; **37**: 362-368 [PMID: 28731786 DOI: 10.1089/jir.2017.0040]

25 **Chang KC**, Ye YH, Wu CK, Lin MT, Tsai MC, Tseng PL, Hu TH. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. *J Formos Med Assoc* 2018; **117**: 1011-1018 [PMID: 29254684 DOI: 10.1016/j.jfma.2017.11.008]

26 **Kim JH**, Lee M, Park SW, Kang M, Kim M, Lee SH, Kim TS, Park JM, Choi DH. Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis. *Medicine (Baltimore)* 2018; **97**: e13438 [PMID: 30508959 DOI: 10.1097/MD.0000000000013438]

27 **Song BG**, Sinn DH, Chi S, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. *Eur J Gastroenterol Hepatol* 2018; **30**: 1447-1452 [PMID: 30063482 DOI: 10.1097/MEG.0000000000001226]

28 **Sou FM**, Wu CK, Chang KC, Lu SN, Wang JH, Hung CH, Chen CH, Kee KM, Yen YH, Lin MT, Tsai MC, Hu TH. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. *J Formos Med Assoc* 2019; **118**: 504-513 [PMID: 30527565 DOI: 10.1016/j.jfma.2018.10.017]

29 **Yoshimasu Y**, Furuichi Y, Kasai Y, Takeuchi H, Sugimoto K, Nakamura I, Itoi T. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C. *J Gastrointestin Liver Dis* 2019; **28**: 63-71 [PMID: 30851174 DOI: 10.15403/jgld.2014.1121.281.hpc]

30 **Sahin T**, Serin A, Emek E, Bozkurt B, Arikan BT, Tokat Y. Effectiveness of Noninvasive Fibrosis Markers for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis. *Transplant Proc* 2019; **51**: 2397-2402 [PMID: 31402255 DOI: 10.1016/j.transproceed.2019.01.193]

31 **Yu ML**, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, Lee LP, Lin ZY, Hsieh MY, Wang LY, Chuang WL, Liaw YF. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. *Hepatology* 2006; **44**: 1086-1097 [PMID: 17058238 DOI: 10.1002/hep.21363]

32 **Kim MN**, Lee JH, Chon YE, Ha Y, Hwang SG. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy. *Eur J Gastroenterol Hepatol* 2020; **32**: 433-439 [PMID: 31490417 DOI: 10.1097/MEG.0000000000001520]

33 **Reddy N**, Naylor P, Hakim Z, Asbahi R, Ravindran K, May E, Ehrinpreis M, Mutchnick M. Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans. *J Clin Transl Hepatol* 2015; **3**: 163-168 [PMID: 26623262 DOI: 10.14218/JCTH.2015.00013]

34 **Hann HW**, Wan S, Lai Y, Hann RS, Myers RE, Patel F, Zhang K, Ye Z, Wang C, Yang H. Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. *J Gastroenterol Hepatol* 2015; **30**: 131-138 [PMID: 24995497 DOI: 10.1111/jgh.12664]

35 **Chen TM**, Lin CC, Huang PT, Wen CF. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy. *Tumour Biol* 2016; **37**: 7129-7137 [PMID: 26662957 DOI: 10.1007/s13277-015-4593-6]

36 **Kim JH**, Kim JW, Seo JW, Choe WH, Kwon SY. Noninvasive Tests for Fibrosis Predict 5-Year Mortality and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. *J Clin Gastroenterol* 2016; **50**: 882-888 [PMID: 27322532 DOI: 10.1097/MCG.0000000000000574]

37 **Lee K**, Sinn DH, Gwak GY, Cho HC, Jung SH, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. *Gut Liver* 2016; **10**: 796-802 [PMID: 27114418 DOI: 10.5009/gnl15368]

38 **Ng KJ**, Tseng CW, Chang TT, Tzeng SJ, Hsieh YH, Hung TH, Huang HT, Wu SF, Tseng KC. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. *Clin Interv Aging* 2016; **11**: 1035-1041 [PMID: 27536084 DOI: 10.2147/CIA.S108589]

39 **Wu CK**, Chang KC, Hung CH, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hu TH. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. *J Antimicrob Chemother* 2016; **71**: 1943-1947 [PMID: 27073265 DOI: 10.1093/jac/dkw097]

40 **Giannini EG**, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F, Zentilin P, Savarino V. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. *Eur J Clin Invest* 2019; **49**: e13056 [PMID: 30474209 DOI: 10.1111/eci.13056]

41 **Li Q**, Ren X, Lu C, Li W, Huang Y, Chen L. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study. *Medicine (Baltimore)* 2017; **96**: e6336 [PMID: 28328813 DOI: 10.1097/MD.0000000000006336]

42 **Li Q**, Chen L, Zhou Y. Diagnostic accuracy of liver stiffness measurement in chronic hepatitis B patients with normal or mildly elevated alanine transaminase levels. *Sci Rep* 2018; **8**: 5224 [PMID: 29588489 DOI: 10.1038/s41598-018-23646-2]

43 **Sterling RK**, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006; **43**: 1317-1325 [PMID: 16729309 DOI: 10.1002/hep.21178]

44 **Park LS**, Tate JP, Justice AC, Lo Re V 3rd, Lim JK, Bräu N, Brown ST, Butt AA, Gibert C, Goetz MB, Rimland D, Rodriguez-Barradas MC, Dubrow R. FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. *Cancer Epidemiol Biomarkers Prev* 2011; **20**: 2512-2517 [PMID: 22028407 DOI: 10.1158/1055-9965.EPI-11-0582]

45 **Kanwal F**, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. *Hepatology* 2020; **71**: 44-55 [PMID: 31222774 DOI: 10.1002/hep.30823]

46 **Suh B**, Park S, Shin DW, Yun JM, Yang HK, Yu SJ, Shin CI, Kim JS, Ahn E, Lee H, Park JH, Cho B. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. *Hepatology* 2015; **61**: 1261-1268 [PMID: 25502481 DOI: 10.1002/hep.27654]

47 **Suh B**, Yun JM, Park S, Shin DW, Lee TH, Yang HK, Ahn E, Lee H, Park JH, Cho B. Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB-4 liver fibrosis index. *Cancer* 2015; **121**: 3818-3825 [PMID: 26178294 DOI: 10.1002/cncr.29577]

48 **Tseng TC**, Liu CJ, Su TH, Yang WT, Chen CL, Yang HC, Wang CC, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. *Am J Gastroenterol* 2017; **112**: 1564-1574 [PMID: 28853728 DOI: 10.1038/ajg.2017.254]

49 **Chon YE**, Jung ES, Park JY, Kim DY, Ahn SH, Han KH, Chon CY, Jung KS, Kim SU. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. *J Clin Gastroenterol* 2012; **46**: 518-525 [PMID: 22688146 DOI: 10.1097/MCG.0b013e31825079f1]

50 **Tamaki N**, Kurosaki M, Matsuda S, Muraoka M, Yasui Y, Suzuki S, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. *J Gastroenterol* 2014; **49**: 1495-1503 [PMID: 24337828 DOI: 10.1007/s00535-013-0914-y]

51 **Ito T**, Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S. Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. *J Viral Hepat* 2015; **22**: 777-783 [PMID: 25608086 DOI: 10.1111/jvh.12389]

52 **Toyoda H**, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Ito T. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. *J Gastroenterol Hepatol* 2015; **30**: 1183-1189 [PMID: 25678094 DOI: 10.1111/jgh.12915]

53 **Fusco M**, Piselli P, Virdone S, Di Cicco P, Scognamiglio P, De Paoli P, Ciullo V, Verdirosi D, D'Orazio M, Dal Maso L, Girardi E, Franceschi S, Serraino D. Infection with hepatitis viruses, FIB-4 index and risk of hepatocellular carcinoma in southern Italy: a population-based cohort study. *Infect Agent Cancer* 2016; **11**: 54 [PMID: 27822295 DOI: 10.1186/s13027-016-0101-x]

54 **Butt AA**, Ren Y, Lo Re V 3rd, Taddei TH, Kaplan DE. Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. *Clin Infect Dis* 2017; **65**: 64-72 [PMID: 28369305 DOI: 10.1093/cid/cix224]

55 **Peleg N**, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A. Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. *PLoS One* 2018; **13**: e0202393 [PMID: 30106985 DOI: 10.1371/journal.pone.0202393]

56 **Ioannou GN**, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. *Gastroenterology* 2019; **157**: 1264-1278.e4 [PMID: 31356807 DOI: 10.1053/j.gastro.2019.07.033]

57 **Alexander M**, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Waterworth DM, Kendrick S, Sattar N, Alazawi W. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. *BMC Med* 2019; **17**: 95 [PMID: 31104631 DOI: 10.1186/s12916-019-1321-x]

58 **Li X**, Xu H, Gao P. Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients. *Med Sci Monit* 2019; **25**: 7243-7250 [PMID: 31558693 DOI: 10.12659/MSM.918784]

59 **Watanabe T**, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Hirooka M, Abe M, Hiasa Y. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. *Hepatol Res* 2019; **49**: 136-146 [PMID: 30335208 DOI: 10.1111/hepr.13278]

60 **Degasperi E**, D'Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Lunghi G, Colombo M, Lampertico P. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. *Clin Gastroenterol Hepatol* 2019; **17**: 1183-1191.e7 [PMID: 30613002 DOI: 10.1016/j.cgh.2018.10.038]

61 **Cheng PN**, Chiu HC, Chiu YC, Chen SC, Chen Y. Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community. *PLoS One* 2018; **13**: e0206947 [PMID: 30403744 DOI: 10.1371/journal.pone.0206947]

62 **Chayanupatkul M**, Kanwal F. Reply to: "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients". *J Hepatol* 2017; **67**: 884-885 [PMID: 28636899 DOI: 10.1016/j.jhep.2017.06.004]

63 **Forns X**, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology* 2002; **36**: 986-992 [PMID: 12297848 DOI: 10.1053/jhep.2002.36128]

64 **Bourliere M**, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, Lecomte L, Castellani P, Rosenthal-Allieri MA, Gerolami R, Ouzan D, Deydier R, Degott C, Halfon P. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. *J Viral Hepat* 2006; **13**: 659-670 [PMID: 16970597 DOI: 10.1111/j.1365-2893.2006.00736.x]

65 **D'Ambrosio R**, Aghemo A, Rumi MG, Degasperi E, Sangiovanni A, Maggioni M, Fraquelli M, Perbellini R, Rosenberg W, Bedossa P, Colombo M, Lampertico P. Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. *Liver Int* 2018; **38**: 1459-1467 [PMID: 29377616 DOI: 10.1111/liv.13707]

66 **Lok AS**, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. *Hepatology* 2005; **42**: 282-292 [PMID: 15986415 DOI: 10.1002/hep.20772]

67 **Mobarak L**, Omran D, Nabeel MM, Zakaria Z. Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease. *J Med Virol* 2017; **89**: 1062-1068 [PMID: 27769108 DOI: 10.1002/jmv.24720]

68 **Johnson PJ**, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. *J Clin Oncol* 2015; **33**: 550-558 [PMID: 25512453 DOI: 10.1200/JCO.2014.57.9151]

69 **Toyoda H**, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, Fox RP, Yeo W, Mo F, Chan AW, Tada T, Iñarrairaegui M, Vogel A, Schweitzer N, Chan SL, Sangro B, Kumada T, Johnson PJ. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. *Br J Cancer* 2016; **114**: 744-750 [PMID: 27022825 DOI: 10.1038/bjc.2016.33]

70 **Gui B**, Weiner AA, Nosher J, Lu SE, Foltz GM, Hasan O, Kim SK, Gendel V, Mani NB, Carpizo DR, Saad NE, Kennedy TJ, Zuckerman DA, Olsen JR, Parikh PJ, Jabbour SK. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization. *Am J Clin Oncol* 2018; **41**: 861-866 [PMID: 28418940 DOI: 10.1097/COC.0000000000000384]

71 **Ho SY**, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, Huang YH, Lee FY, Hou MC, Tsai YJ, Huo TI. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *PLoS One* 2017; **12**: e0180408 [PMID: 28672011 DOI: 10.1371/journal.pone.0180408]

72 **Chen PC**, Chiu NC, Su CW, Huang YH, Hou MC, Lin HC, Wu JC. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. *J Chin Med Assoc* 2019; **82**: 2-10 [PMID: 30839396 DOI: 10.1097/JCMA.0000000000000001]

73 **Casadei Gardini A**, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G, Buonfiglioli F, Vitale G, Ravaioli F, Gitto S, Verucchi G, Lenzi M, Bolondi L, Mazzella G, Brillanti S, Andreone P; member of the Bologna DAA group. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. *Dig Liver Dis* 2019; **51**: 681-688 [PMID: 30327251 DOI: 10.1016/j.dld.2018.09.016]

74 **Fujita K**, Oura K, Yoneyama H, Shi T, Takuma K, Nakahara M, Tadokoro T, Nomura T, Morishita A, Tsutsui K, Himoto T, Masaki T. Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. *Hepatol Res* 2019; **49**: 731-742 [PMID: 30892804 DOI: 10.1111/hepr.13333]

75 **Liu PH**, Hsu CY, Hsia CY, Lee YH, Chiou YY, Huang YH, Lee FY, Lin HC, Hou MC, Huo TI. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. *J Gastroenterol Hepatol* 2017; **32**: 879-886 [PMID: 27696519 DOI: 10.1111/jgh.13608]

76 **Ho CHM**, Chiang CL, Lee FAS, Choi HCW, Chan JCH, Yeung CSY, Huang JJ, Chan MKH, Blanck O, Wong FCS. Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and child-pugh (CP) score for predicting of survival in advanced hcc patients receiving radiotherapy (RT). *Oncotarget* 2018; **9**: 28818-28829 [PMID: 29988960 DOI: 10.18632/oncotarget.25522]

77 **Roayaie S,** Jibara G, Berhane S, Tabrizian P, Park JW, Yang J, Yan L, Han G, Izzo F, Chen M, Blanc JF, Kudo M, Roberts LR, Sherman M, Johnson P. PALBI-an objective score based on platelets, albumin bilirubin stratifies HCC patients undergoing resection & ablation better than Child’s classification. *Hepatology* 2015; **62**: S1851 [DOI: 10.1002/hep.28162]

78 **Oikonomou T**, Goulis L, Doumtsis P, Tzoumari T, Akriviadis E, Cholongitas E. ALBI and PALBI Grades Are Associated with the Outcome of Patients with Stable Decompensated Cirrhosis. *Ann Hepatol* 2019; **18**: 126-136 [PMID: 31113581 DOI: 10.5604/01.3001.0012.7904]

79 **Elshaarawy O**, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A, Rewisha E, Waked I. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. *World J Hepatol* 2019; **11**: 542-552 [PMID: 31293722 DOI: 10.4254/wjh.v11.i6.542]

80 **Vos JJ**, Wietasch JK, Absalom AR, Hendriks HG, Scheeren TW. Green light for liver function monitoring using indocyanine green? An overview of current clinical applications. *Anaesthesia* 2014; **69**: 1364-1376 [PMID: 24894115 DOI: 10.1111/anae.12755]

81 **Halle BM**, Poulsen TD, Pedersen HP. Indocyanine green plasma disappearance rate as dynamic liver function test in critically ill patients. *Acta Anaesthesiol Scand* 2014; **58**: 1214-1219 [PMID: 25307706 DOI: 10.1111/aas.12406]

82 **Lisotti A**, Azzaroli F, Buonfiglioli F, Montagnani M, Cecinato P, Turco L, Calvanese C, Simoni P, Guardigli M, Arena R, Cucchetti A, Colecchia A, Festi D, Golfieri R, Mazzella G. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. *Hepatology* 2014; **59**: 643-650 [PMID: 24038116 DOI: 10.1002/hep.26700]

83 **Pind ML**, Bendtsen F, Kallemose T, Møller S. Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis. *Eur J Gastroenterol Hepatol* 2016; **28**: 948-954 [PMID: 27172450 DOI: 10.1097/MEG.0000000000000611]

84 **Lisotti A**, Azzaroli F, Cucchetti A, Buonfiglioli F, Cecinato P, Calvanese C, Simoni P, Arena R, Montagnani M, Golfieri R, Colecchia A, Festi D, Mazzella G. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. *Liver Int* 2016; **36**: 1313-1321 [PMID: 26786880 DOI: 10.1111/liv.13070]

85 **Song P**, Inagaki Y, Wang Z, Hasegawa K, Sakamoto Y, Arita J, Tang W, Kokudo N. High Levels of Gamma-Glutamyl Transferase and Indocyanine Green Retention Rate at 15 min as Preoperative Predictors of Tumor Recurrence in Patients With Hepatocellular Carcinoma. *Medicine (Baltimore)* 2015; **94**: e810 [PMID: 26020384 DOI: 10.1097/MD.0000000000000810]

86 **Escorsell À**, Mas A, Fernández J, García-Valdecasas JC. Limitations of use of the noninvasive clearance of indocyanine green as a prognostic indicator of graft function in liver transplantation. *Transplant Proc* 2012; **44**: 1539-1541 [PMID: 22841207 DOI: 10.1016/j.transproceed.2012.05.023]

87 **Kim DY**, Kim SU, Ahn SH, Park JY, Lee JM, Park YN, Yoon KT, Paik YH, Lee KS, Chon CY, Han KH. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. *Dig Dis Sci* 2009; **54**: 1758-1763 [PMID: 19005758 DOI: 10.1007/s10620-008-0541-2]

88 **Vizzutti F**, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G, Zignego AL, Marra F, Laffi G, Pinzani M. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. *Hepatology* 2007; **45**: 1290-1297 [PMID: 17464971 DOI: 10.1002/hep.21665]

89 **Feier D**, Lupsor Platon M, Stefanescu H, Badea R. Transient elastography for the detection of hepatocellular carcinoma in viral C liver cirrhosis. Is there something else than increased liver stiffness? *J Gastrointestin Liver Dis* 2013; **22**: 283-289 [PMID: 24078985]

90 **Jung KS**, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, Chon CY, Choi EH, Han KH. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). *Hepatology* 2011; **53**: 885-894 [PMID: 21319193 DOI: 10.1002/hep.24121]

91 **Fung J**, Poon RT, Yu WC, Chan SC, Chan AC, Chok KS, Cheung TT, Seto WK, Lo CM, Lai CL, Yuen MF. Use of liver stiffness measurement for liver resection surgery: correlation with indocyanine green clearance testing and post-operative outcome. *PLoS One* 2013; **8**: e72306 [PMID: 24015232 DOI: 10.1371/journal.pone.0072306]

92 **Kim SU**, Lee JH, Kim DY, Ahn SH, Jung KS, Choi EH, Park YN, Han KH, Chon CY, Park JY. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. *PLoS One* 2012; **7**: e36676 [PMID: 22574212 DOI: 10.1371/journal.pone.0036676]

93 **Kim DY**, Song KJ, Kim SU, Yoo EJ, Park JY, Ahn SH, Han KH. Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. *Onco Targets Ther* 2013; **6**: 1463-1469 [PMID: 24204161 DOI: 10.2147/OTT.S51986]

94 **Robic MA**, Procopet B, Métivier S, Péron JM, Selves J, Vinel JP, Bureau C. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. *J Hepatol* 2011; **55**: 1017-1024 [PMID: 21354450 DOI: 10.1016/j.jhep.2011.01.051]

95 **Klibansky DA**, Mehta SH, Curry M, Nasser I, Challies T, Afdhal NH. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. *J Viral Hepat* 2012; **19**: e184-e193 [PMID: 22239518 DOI: 10.1111/j.1365-2893.2011.01493.x]

96 **Poynard T**, Vergniol J, Ngo Y, Foucher J, Munteanu M, Merrouche W, Colombo M, Thibault V, Schiff E, Brass CA, Albrecht JK, Rudler M, Deckmyn O, Lebray P, Thabut D, Ratziu V, de Ledinghen V; FibroFrance Study Group; Epic3 Study Group; Bordeaux HCV Study Group. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). *J Hepatol* 2014; **60**: 706-714 [PMID: 24291240 DOI: 10.1016/j.jhep.2013.11.016]

97 **Calvaruso V,** Bronte F, Simone F, Bavetta MG, Conte E, Craxì A, Di Marco V. P.11.9 Liver stiffness at baseline predicts decompensation and hepatocellular carcinoma in patients with compensated hcv cirrhosis. *Dig Liver Dis* 2013; **45**: S167–168 [DOI: 10.1016/s1590-8658(13)60474-0]

98 **Salmon D**, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. *J Hepatol* 2012; **56**: 862-868 [PMID: 22173166 DOI: 10.1016/j.jhep.2011.11.009]

99 **Pérez-Latorre L**, Sánchez-Conde M, Rincón D, Miralles P, Aldámiz-Echevarría T, Carrero A, Tejerina F, Díez C, Bellón JM, Bañares R, Berenguer J. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography. *Clin Infect Dis* 2014; **58**: 713-718 [PMID: 24265358 DOI: 10.1093/cid/cit768]

100 **Wong GL**, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Wong VW. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. *J Hepatol* 2014; **60**: 339-345 [PMID: 24128413 DOI: 10.1016/j.jhep.2013.09.029]

101 **Li ZQ**, Hu CL, Yu P, Gu XY, Zhang JJ, Li H, Zhang HY, Lv J, Liu YM, Zeng QL, Yan JY, Yu ZJ, Zhang Y. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. *Clin Res Hepatol Gastroenterol* 2017; **41**: 311-318 [PMID: 28237828 DOI: 10.1016/j.clinre.2016.11.007]

102 **Kim MN**, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Song KJ, Park YN, Han KH. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. *Hepatology* 2015; **61**: 1851-1859 [PMID: 25643638 DOI: 10.1002/hep.27735]

103 **Wang JH**, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. *Liver Int* 2016; **36**: 1793-1799 [PMID: 27254286 DOI: 10.1111/liv.13179]

104 **Jeon MY**, Lee HW, Kim SU, Heo JY, Han S, Kim BK, Park JY, Kim DY, Ahn SH, Han KH. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. *Hepatol Int* 2017; **11**: 268-276 [PMID: 28224351 DOI: 10.1007/s12072-017-9789-y]

105 **Adler M**, Larocca L, Trovato FM, Marcinkowski H, Pasha Y, Taylor-Robinson SD. Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study. *HPB (Oxford)* 2016; **18**: 678-683 [PMID: 27485062 DOI: 10.1016/j.hpb.2016.05.005]

106 **Bihari C**, Rastogi A, Sen B, Bhadoria AS, Maiwall R, Sarin SK. Quantitative fibrosis estimation by image analysis predicts development of decompensation, composite events and defines event-free survival in chronic hepatitis B patients. *Hum Pathol* 2016; **55**: 63-71 [PMID: 27189343 DOI: 10.1016/j.humpath.2016.04.012]

107 **Seo YS**, Kim MN, Kim SU, Kim SG, Um SH, Han KH, Kim YS. Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. *Medicine (Baltimore)* 2016; **95**: e2985 [PMID: 27015173 DOI: 10.1097/MD.0000000000002985]

108 **D’Ambrosio R,** Degasperi E, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Perbellini R, Lunghi G, Lampertico P. Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: A single-center prospective 3-year study. *Dig Liver Dis* 2018; **50**: 36 [DOI: 10.1016/j.dld.2018.01.109]

109 **Wang JH**, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. *Kaohsiung J Med Sci* 2019; **35**: 708-714 [PMID: 31430035 DOI: 10.1002/kjm2.12114]

110 **Masuzaki R**, Tateishi R, Yoshida H, Yoshida H, Sato S, Kato N, Kanai F, Sugioka Y, Ikeda H, Shiina S, Kawabe T, Omata M. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. *J Clin Gastroenterol* 2008; **42**: 839-843 [PMID: 18668703 DOI: 10.1097/mcg.0b013e318050074f]

111 **Rinaldi L**, Guarino M, Perrella A, Pafundi PC, Valente G, Fontanella L, Nevola R, Guerrera B, Iuliano N, Imparato M, Trabucco A, Sasso FC, Morisco F, Ascione A, Piai G, Adinolfi LE. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. *Dig Dis Sci* 2019; **64**: 3013-3019 [PMID: 30937719 DOI: 10.1007/s10620-019-05604-8]

112 **Izumi T**, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N. Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. *Hepatol Res* 2019; **49**: 1207-1217 [PMID: 31219667 DOI: 10.1111/hepr.13391]

113 **Pons M**, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, Buti M, Augustin S, Forns X, Mínguez B, Genescà J. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. *J Hepatol* 2020; **72**: 472-480 [PMID: 31629779 DOI: 10.1016/j.jhep.2019.10.005]

114 **Nakagomi R**, Tateishi R, Masuzaki R, Soroida Y, Iwai T, Kondo M, Fujiwara N, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Kato N, Moriya K, Ikeda H, Koike K. Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment. *J Gastroenterol Hepatol* 2019; **34**: 921-928 [PMID: 30393960 DOI: 10.1111/jgh.14530]

115 **Masuzaki R**, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. *Hepatology* 2009; **49**: 1954-1961 [PMID: 19434742 DOI: 10.1002/hep.22870]

116 **Nahon P**, Kettaneh A, Lemoine M, Seror O, Barget N, Trinchet JC, Beaugrand M, Ganne-Carrié N. Liver stiffness measurement in patients with cirrhosis and hepatocellular carcinoma: a case-control study. *Eur J Gastroenterol Hepatol* 2009; **21**: 214-219 [PMID: 19212210 DOI: 10.1097/MEG.0b013e32830eb8d7]

117 **Kuo YH**, Lu SN, Hung CH, Kee KM, Chen CH, Hu TH, Lee CM, Changchien CS, Wang JH. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. *Hepatol Int* 2010; **4**: 700-706 [PMID: 21286340 DOI: 10.1007/s12072-010-9223-1]

118 **Akima T**, Tamano M, Hiraishi H. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis. *Hepatol Res* 2011; **41**: 965-970 [PMID: 21883739 DOI: 10.1111/j.1872-034X.2011.00846.x]

119 **Wang HM**, Hung CH, Lu SN, Chen CH, Lee CM, Hu TH, Wang JH. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. *Liver Int* 2013; **33**: 756-761 [PMID: 23405889 DOI: 10.1111/liv.12118]

120 **Narita Y**, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy. *J Gastroenterol Hepatol* 2014; **29**: 137-143 [PMID: 24117602 DOI: 10.1111/jgh.12401]

121 **Corma-Gómez A**, Macías J, Téllez F, Freyre-Carrillo C, Morano L, Rivero-Juárez A, Ríos MJ, Alados JC, Vera-Méndez FJ, Merchante N, Palacios R, Granados R, Merino D, De Los Santos I, Pineda JA. Liver stiffness at the time of sustained virological response predicts the clinical outcome in HIV/HCV-coinfected patients with advanced fibrosis treated with direct-acting antivirals. *Clin Infect Dis* 2019: ciz1140 [PMID: 31754695 DOI: 10.1093/cid/ciz1140]

122 **Ravaioli F**, Conti F, Brillanti S, Andreone P, Mazzella G, Buonfiglioli F, Serio I, Verrucchi G, Bacchi Reggiani ML, Colli A, Marasco G, Colecchia A, Festi D. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. *Dig Liver Dis* 2018; **50**: 573-579 [PMID: 29567413 DOI: 10.1016/j.dld.2018.02.010]

123 **Shili-Masmoudi S**, Wong GL, Hiriart JB, Liu K, Chermak F, Shu SS, Foucher J, Tse YK, Bernard PH, Yip TC, Merrouche W, Chan HL, Wong VW, de Lédinghen V. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. *Liver Int* 2020; **40**: 581-589 [PMID: 31749300 DOI: 10.1111/liv.14301]

124 **Kim BK**, Han KH, Park JY, Ahn SH, Kim JK, Paik YH, Lee KS, Chon CY, Kim DY. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. *Am J Gastroenterol* 2010; **105**: 1382-1390 [PMID: 20087336 DOI: 10.1038/ajg.2009.750]

125 **Shin SH**, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. *Liver Int* 2015; **35**: 1054-1062 [PMID: 24930484 DOI: 10.1111/liv.12621]

126 **Marzano A**, Tucci A, Chialà C, Saracco GM, Fadda M, Debernardi Venon W. Liver stiffness-based model for portal hypertension and hepatocellular cancer risk in HBV responsive to antivirals. *Minerva Gastroenterol Dietol* 2019; **65**: 11-19 [PMID: 30356037 DOI: 10.23736/S1121-421X.18.02534-5]

127 **Grossi G**, Viganò M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). *Liver Int* 2017; **37 Suppl 1**: 45-51 [PMID: 28052621 DOI: 10.1111/liv.13291]

128 **Castera L**, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. *J Hepatol* 2012; **56**: 696-703 [PMID: 21767510 DOI: 10.1016/j.jhep.2011.07.005]

129 **Ravaioli F**, Montagnani M, Lisotti A, Festi D, Mazzella G, Azzaroli F. Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. *Gastroenterol Res Pract* 2018; **2018**: 4202091 [PMID: 29977287 DOI: 10.1155/2018/4202091]

130 **Singh S**, Eaton JE, Murad MH, Tanaka H, Iijima H, Talwalkar JA. Accuracy of spleen stiffness measurement in detection of esophageal varices in patients with chronic liver disease: systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2014; **12**: 935-45.e4 [PMID: 24055985 DOI: 10.1016/j.cgh.2013.09.013]

131 **Ma X**, Wang L, Wu H, Feng Y, Han X, Bu H, Zhu Q. Spleen Stiffness Is Superior to Liver Stiffness for Predicting Esophageal Varices in Chronic Liver Disease: A Meta-Analysis. *PLoS One* 2016; **11**: e0165786 [PMID: 27829057 DOI: 10.1371/journal.pone.0165786]

132 **Berzigotti A**, Seijo S, Arena U, Abraldes JG, Vizzutti F, García-Pagán JC, Pinzani M, Bosch J. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. *Gastroenterology* 2013; **144**: 102-111.e1 [PMID: 23058320 DOI: 10.1053/j.gastro.2012.10.001]

133 **Colecchia A**, Montrone L, Scaioli E, Bacchi-Reggiani ML, Colli A, Casazza G, Schiumerini R, Turco L, Di Biase AR, Mazzella G, Marzi L, Arena U, Pinzani M, Festi D. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. *Gastroenterology* 2012; **143**: 646-654 [PMID: 22643348 DOI: 10.1053/j.gastro.2012.05.035]

134 **Berzigotti A**. Non-invasive evaluation of portal hypertension using ultrasound elastography. *J Hepatol* 2017; **67**: 399-411 [PMID: 28223101 DOI: 10.1016/j.jhep.2017.02.003]

135 **Colecchia A**, Colli A, Casazza G, Mandolesi D, Schiumerini R, Reggiani LB, Marasco G, Taddia M, Lisotti A, Mazzella G, Di Biase AR, Golfieri R, Pinzani M, Festi D. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. *J Hepatol* 2014; **60**: 1158-1164 [PMID: 24607624 DOI: 10.1016/j.jhep.2014.02.024]

136 **Marasco G**, Colecchia A, Dajti E, Ravaioli F, Cucchetti A, Cescon M, Festi D. Prediction of posthepatectomy liver failure: Role of SSM and LSPS. *J Surg Oncol* 2019; **119**: 400-401 [PMID: 30561034 DOI: 10.1002/jso.25345]

137 **Colecchia A**, Marasco G, Taddia M, Montrone L, Eusebi LH, Mandolesi D, Schiumerini R, Di Biase AR, Festi D. Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients: a review of the literature. *Eur J Gastroenterol Hepatol* 2015; **27**: 992-1001 [PMID: 26020376 DOI: 10.1097/MEG.0000000000000393]

138 **Colecchia A**, Ravaioli F, Marasco G, Colli A, Dajti E, Di Biase AR, Bacchi Reggiani ML, Berzigotti A, Pinzani M, Festi D. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. *J Hepatol* 2018; **69**: 308-317 [PMID: 29729368 DOI: 10.1016/j.jhep.2018.04.023]

139 **Ravaioli F**, Colecchia A, Dajti E, Marasco G, Alemanni LV, Tamè M, Azzaroli F, Brillanti S, Mazzella G, Festi D. Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. *World J Hepatol* 2018; **10**: 731-742 [PMID: 30386466 DOI: 10.4254/wjh.v10.i10.731]

140 **Dajti E**, Ravaioli F, Colecchia A, Marasco G, Calès P, Festi D. "Are the Expanded Baveno VI Criteria really safe to screen compensated cirrhotic patients for high-risk varices?" *Dig Liver Dis* 2019; **51**: 456-457 [PMID: 30635194 DOI: 10.1016/j.dld.2018.12.013]

141 **Stefanescu H**, Marasco G, Calès P, Fraquelli M, Rosselli M, Ganne-Carriè N, de Ledinghen V, Ravaioli F, Colecchia A, Rusu C, Andreone P, Mazzella G, Festi D. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. *Liver Int* 2020; **40**: 175-185 [PMID: 31444849 DOI: 10.1111/liv.14228]

142 **Calès P**, Buisson F, Ravaioli F, Berger A, Carboni C, Marasco G, Festi D. How to clarify the Baveno VI criteria for ruling out varices needing treatment by noninvasive tests. *Liver Int* 2019; **39**: 49-53 [PMID: 30129700 DOI: 10.1111/liv.13945]

143 **Marasco G**, Colecchia A, Colli A, Ravaioli F, Casazza G, Bacchi Reggiani ML, Cucchetti A, Cescon M, Festi D. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. *J Hepatol* 2019; **70**: 440-448 [PMID: 30389551 DOI: 10.1016/j.jhep.2018.10.022]

144 **Rappaport AM**, MacPhee PJ, Fisher MM, Phillips MJ. The scarring of the liver acini (Cirrhosis). Tridimensional and microcirculatory considerations. *Virchows Arch A Pathol Anat Histopathol* 1983; **402**: 107-137 [PMID: 6420982 DOI: 10.1007/bf00695054]

145 **Onori P**, Morini S, Franchitto A, Sferra R, Alvaro D, Gaudio E. Hepatic microvascular features in experimental cirrhosis: a structural and morphometrical study in CCl4-treated rats. *J Hepatol* 2000; **33**: 555-563 [PMID: 11059860 DOI: 10.1034/j.1600-0641.2000.033004555.x]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 14, 2020

**First decision:** March 24, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P- Reviewer:** Guo K, Rong G **S- Editor:** Wang JL **L- Editor:** **E- Editor:**

**Table 1 Studies reporting the role of aspartate aminotransferase to platelet ratio index in predicting hepatocellular carcinoma**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Etiology** | **Patients****(*n*)** | **Follow-up (mo)** | **Region** | **HCC****(*n*)** | **AUROC** | **Cut-off** |
| Yu *et al*[31], 2006 | HCV IFN-based treated | 776 | 62.5 | Asia | 41 | 0.870 | 0.75 all patients0.5 SVR1.5 no-SVR |
| Yu *et al*[31], 2006 | HCV untreated | 562 | 61.8 | Asia | 54 | 0.715  | 1.5 |
| Reddy *et al*[33], 2015 | HCV SVR IFN-treated | 22 | 96 | America | 0 | - | - |
| Reddy *et al*[33], 2015 | HCV untreated | 203 | 96 | America | 51 | - | - |
| Hann *et al*[34], 2015 | HBV | 855 | 52.4  | America; Asia | 82 | - | - |
| Chen *et al*[35], 2016 | HCV SVR | 540 | 41.4  | Asia | 15 | - | > 0.5 |
| Chen *et al*[35], 2016 | HCV (no-SVR) | 183 | 36.8  | Asia | 14 | - | > 1.5 |
| Kim *et al*[36], 2016 | HBV | 542 | 60 | Asia | 68 | 0.731   | >0.766  |
| Lee *et al*[37], 2016 | HCV | 598 | 61.2 | Asia | 8 |  | 1 |
| Ng *et al*[38], 2016 | HCV | 105 | 40.56 | Asia | 15 | - | 2 |
| Wu *et al*[39], 2016 | HCV SVR | 1351 | 6 after SVR | Asia | 49 | - | 0.7 |
| Toyoda *et al*[21], 2017 | HCV SVR; Training cohort | 522 | 104 | Asia | 21 | - | 0.73 |
| Toyoda *et al*[21], 2017 | HCV SVR; Validation cohort | 309 | 87,6 | Asia | 17 | - | 0,73 |
| Cheung *et al*[22], 2017 | PBC | 144 | 82.8 | Asia | 12 | 0.77 | 0.54 |
| Nishikawa *et al*[23], 2017 | HBV | 338 | 59.8 | Asia | 33 | 0.601 | 0.78 |
| Ji *et al*[24], 2017 | HCV SVR | 34 | 41.4 | Asia | 5 |  | 1.5 |
| Paik *et al*[16], 2018 | HBV | 1006 | 61.2 | Asia | 36 | 0.76 | 0.5 |
| Chang *et al*[25], 2018 | HCV (no-SVR) | 800 | 53.5 | Asia | 100 | - | 2.57 |
| Kim *et al*[26], 2018 | ALD | 924 | 36 | Asia | 83 | 0.61 | 1 |
| Song *et al*[27], 2018 | HBV | 1014 | 46.8 | Asia | 37 | - | 0.5 |
| Sou *et al*[28], 2018 | HCV SVR; IFN-treatment | 1351 | 6 after SVR | Asia | 47 | - | 0,7 |
| Sou *et al*[28], 2018 | HCV no SVR | 536 | 6 post treatment | Asia | 75 | - | 0,7 |
| Na *et al*[20], 2019 | HCV SVR | 295 | 89.2 | Asia | 12 | 0.89 | 2 |
| Yoshimasu *et al*[29], 2019 | HCV DAAs | 211 | 6 after DAAs | Asia | 2 | - | - |
| Sahin *et al*[30], 2019 | HBVHBV+HDV | 361 | - | Europe | 115 | - | - |
| Kim *et al*[32], 2020 | HBV | 444 | 94.2 | Asia | 25 | 0.572  | - |

HCC: Hepatocellular carcinoma; AUROC: Area under receiving operating characteristics curve; HCV: Hepatitis virus C; IFN: Interferon; SVR: Sustained virologic response; HBV: Hepatitis virus B; PBC: Primary biliary cholangitis; ALD: Alcoholic liver disease; DAA: Direct acting antiviral agents; HDV: Hepatitis D virus.

**Table 2 Studies reporting the role of fibrosis-4 index in predicting hepatocellular carcinoma**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Etiology** | **Patients (*n*)** | **Follow-up (mo)** | **Region** | **HCC (*n*)** | **AUROC** | **Cut-offs** |
| Park *et al*[44], 2011 | HIV with HCV, HBV, ALD | 22980 | - | United States | 112 | - | 1.45–3.25; > 3.25 |
| Chon *et al*[49], 2012 | HBV | 1126 | 30.7 | Asia | 63 | 0.744 | - |
| Tamaki *et al*[50], 2014 | HCV | 1046 | 76.8 – 70.8 | Asia | 119 | --0.61 | > 3.25; > 3.25 + ΔFIB-4/ year ≥ 0.3; ΔFIB-4/ year ≥ 0.3 |
| Ito *et al*[51], 2015 | HCV | 516 | 135.6 | Asia | 60 | - | 2.0-4.0; > 4 |
| Toyoda *et al*[52], 2015 | HCV SVR | 522 | 86.4 | Asia | 18 | - | > 2 (at SVR24) |
| Suh *et al*[47], 2015 | HBV | 986 | 64.8 | Asia | - | - | 1.7–2.4; > 2.4 |
| Suh *et al*[46], 2015 | ALD | 6661 | 74.4 | Asia | - | - | 1.75 –2.1; >2.1 |
| Kim *et al*[36], 2016 | HBV | 542 | 60 | Asia | 68 | 0.803 | 2.225 |
| Fusco *et al*[53], 2016 | HBV, HCV, none | 4492 | 96 | Europe | 22 | - | 3.25 |
| Tseng *et al*[48], 2017 | HBV naiveHBV NU | 2075(+532) | 192.2 | Asia | 137(+10) | 0.75 | 1.29 |
| Nishikawa *et al*[23], 2017 | HBV  | 338 | 60  | Asia | 33 | 0.768 | 3.666 |
| Butt *et al*[54], 2017 | HCV | 21116 | 12/36/60 | United States | - | 0.81 - 0.82 | 1.45 |
| Kim *et al*[26], 2018 | ALD | 924 | 36 | Asia | 83 | 0.69 | 3.5 |
| Chang *et al*[25], 2018 | HCV no SVR | 800 | 53.5 | Asia | 100 | - | 2.83 |
| Peleg *et al*[55], 2018 | NAFLD | 153 | 100 | Israel | 6 | - | 2.67 |
| Song *et al*[27], 2018 | HBV | 1014 | 46.8 | Asia | 37 | - | 1.45  |
| Paik *et al*[16], 2018 | HBV | 1006 | 61.2 | Asia | 36 | 0.71 | 1.45  |
| Kanwal *et al*[45], 2019 | HCV SVR post-DAA | 18076 | 43,8 | United States | 544 | - | 3.25; 1.45 |
| Ioannou *et al*[56], 2019 | HCV SVR | 48135 | 64.8 | United States | 1509 | - | 3.25 |
| Alexander *et al*[57], 2019 | NAFLD | 63971 (Fib-4 available) | 39.6 | Europe | - | - | 2.67 |
| Na *et al*[20], 2019 | HCV SVR | 295 | 89.2 | Asia | 12 | 0.860.85 | 3.25 (pre-SVR); 2.5 (SVR) |
| Li *et al*[58], 2019 | HCV | 711 | - | Asia | 249 | 0.961 | 2.18 |
| Watanabe *et al*[59], 2019 | HCV SVR post -DAA | 1174 | 17.9 | Asia | 35 | - | 4 |
| Degasperi *et al*[60], 2019 | HCV SVR post -DAA | 565 | 25 | Europe | 48 | - | 9 |
| Kim *et al*[32], 2020 | HBV | 444 | 84 | Asia | 25 | 0.753 (60 mo); 0.698 (84 mo) | 3.25 |

HCC: Hepatocellular carcinoma; AUROC: Area under receiving operating characteristics curve; HIV: Human immunodeficiency virus; HCV: Hepatitis virus C; HBV: Hepatitis virus B; ALD: Alcoholic liver disease; ∆: Delta; SVR: Sustained virologic response; NU: Nucleoside analogues; NAFLD: Non-alcoholic fatty liver disease; DAA: Direct acting antiviral agents.

**Table 3 Studies reporting the role of transient elastography in predicting hepatocellular carcinoma**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Etiology** | **Patients (*n*)** | **Follow-up (mo)** | **Region** | **HCC (*n*)** | **AUROC** | **Cut-off (kPa)** |
| Masuzaki *et al*[110], 2008 | HCV | 265 | - | Asia | 85  | 0.805 | 25 |
| Nahon *et al*[116], 2009 | HCV | 265 | - | Europe | 66 | - | - |
| Masuzaki *et al*[115], 2009 | HCV | 866 | 36.0 | Asia | 77 | - | 25 |
| Kuo *et al*[117], 2010 | HBV, HCV,non-B/non-C | 435 | - | Asia | 106 | 0.736 | 24 |
| Akima *et al*[118], 2011 | Mixed (HCV: 85%) | 157 | 40.7 | Asia | 41 | 0.787 | 12.5 |
| Jung *et al*[90], 2011 | HBV | 1130 | 30.7 | Asia | 57 | - | 8 |
| Fung *et al*[91], 2011 | HBV | 528 | 35.0 | Asia | 7 | - | 10 |
| Robic *et al*[94], 2011 | Mixed | 100 | 24.0 | Europe | 4 | 0.837 | 21.1 |
| Klibansky *et al*[95], 2012 | Mixed | 667 | 28.7 | USA | 16 | 0.870 | 10.5 |
| Chon *et al*[49], 2012 | HBV | 1126 | 30.7 | Asia | 63 | 0.789 | - |
| Kim *et al*[92], 2012 | HBV | 128 | 27.8 | Asia | 13 | 0.722 | 19 |
| Calvaruso *et al*[97], 2012 | HCV/HIV | 275 | 32 | Europe | - | - | 14-40 |
| Salmon *et al*[98], 2012 | HCV/HIV | 244 | 30 | Europe | 21 | - | 12.5 |
| Perez-Latorre *et al*[99], 2013 | HCV | 60 | 42 | Europe | 7 | 0.77 | 25-40 |
| Feier *et al*[89], 2013 | HCV | 144 | - | Europe | 72 | 0.680 | 38.5 |
| Wang *et al*[119], 2013 | HCV | 198 | 47.8 | Asia | 10 | - | 12 |
| Narita *et al*[120], 2013 | HCV  | 151 | 24.1 | Asia | 9 | - | 14 |
| Kim *et al*[93], 2013 | HBV | 162 | 24.0 | Asia | 12 | 0.736 | 12 |
| Poynard *et al*[96], 2014 | HCV | 3927 | 144 | Europe | 84 | 0.860 | 50 |
| Wong *et al*[100], 2014 | HBV | 1555 | 69 | Asia | 55 | 0.83  | 11 |
| Kim *et al*[102], 2015 | HBV | 2876  | 48.9 | Asia | 52 | ﻿0.532 | 13 |
| Wang *et al*[103], 2016 | HCV | 278 | 91.2 | Asia | 18 | 0.781  | 12 |
| Adler *et al*[105], 2016 | Mixed | 432 | 31.3 | Europe | 41 | - | 20 |
| Bihari *et al*[106], 2016 | HBV | 964 | - | Asia | 14 | 0.767 |  |
| Seo *et al*[107], 2016 | HBV | 381 | 48.1 | Asia | 34 | 0.745 | - |
| Jeon *et al*[104], 2017 | HBV | 540 | 54.1 | Asia | 81 | 0.598  | 13 |
| Li *et al*[101], 2017 | HBV | 1200 | 48 | Asia | 156 | - | - |
| D’Ambrosio *et al*[108], 2018 | HCV | 404 | 36 | Europe | 24 | - | - |
| Wang *et al*[109], 2019 | HBV | 371 | 67.2 | Asia | 27 | 0.636  | 21.5 |
| Degasperi *et al*[60], 2019 | HCV SVR | 546 | 25 | Europe | 28 | - | 30 |
| Rinaldi *et al*[111], 2019 | HCV SVR | 258 | 24 | Europe | 35 | 0.691  | 27.8 |
| Izumi *et al*[112], 2019 | HCV | 419 | 30 | Asia | 32 | 0.806 | 8 |
| Izumi *et al*[112], 2019 | HBV | 377 | 27 | Asia | 23 | 0.795 | 6.2 |
| Izumi *et al*[112], 2019 | NAFLD | 258 | 30 | Asia | 33 | 0.698 | 5.4 |
| Pons *et al*[113], 2019 | HCV SVR | 572 | 33 | Europe | 25 | - | - |
| Nakagomi *et al*[114], 2019 | HCV | 1146 | 78 | Asia | 190 | - | - |

AUROC: Area under receiving operating characteristics curve; kPa: Kilopascal; HCV: Hepatitis virus C; HBV: Hepatitis virus B; HIV: Human immunodeficiency virus; SVR: Sustained virologic response; NAFLD: Non-alcoholic fatty liver disease.